...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
【24h】

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes

机译：安布森坦治疗肺动脉高压：改善预后

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that is associated with severe functional impairment and a poor prognosis. Ambrisentan is a selective endothelin type A receptor antagonist approved for the treatment of patients with PAH World Health Organization group 1. The efficacy and safety of ambrisentan has been evaluated in the ARIES series (Ambrisentan for the Treatment of Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies), which has established its use as both monotherapy or in conjunction with other PAH therapies. Specifically, ambrisentan is effective at increasing exercise tolerance, decreasing the risk of functional class deterioration, and prolonging time to clinical worsening. Further, ambrisentan has a favorable effect on mortality, with an 88% patient survival rate after two years of therapy compared with a 61% survival rate as estimated by the National Institute of Health Registry. Ambrisentan is generally well tolerated in all patient groups, with the main side effects of peripheral edema, sinusitis, flushing, and nasal congestion considered to be mild to moderate in nature. Ambrisentan has several favorable qualities that potentially make it more acceptable to patients, including once-daily administration, limited adverse drug reactions and drug-drug interactions, and minimal risk of liver enzyme elevation. Because of the potential risk of teratogenicity associated with ambrisentan, it is only available through a limited distribution program, ie, LEAP (the Letairis Education and Access Program). Ongoing clinical trials will help to clarify the role of ambrisentan in the treatment of PAH.
机译：摘要：肺动脉高压（PAH）是一种进展性的肺血管疾病，与严重的功能障碍和不良的预后有关。 Ambrisentan是一种经批准可用于治疗PAH世界卫生组织第1组患者的选择性A型内皮素受体拮抗剂。Ambrisentan的疗效和安全性已在ARIES系列中进行了评估（Ambrisentan用于治疗肺动脉高压，随机，双重治疗）。盲法，安慰剂对照，多中心疗效研究），已确立其既可作为单一疗法使用，也可与其他PAH疗法结合使用。具体而言，安布雷森坦可有效提高运动耐量，降低功能性类别恶化的风险以及延长临床恶化的时间。此外，安布雷西坦对死亡率具有有利的影响，经过两年的治疗，患者存活率为88％，而美国国立卫生研究院的估计为61％。 Ambrisentan通常在所有患者组中耐受良好，外周水肿，鼻窦炎，潮红和鼻充血的主要副作用被认为是轻度至中度。 Ambrisentan具有多种有利的品质，可能使它更受患者接受，包括每天给药一次，有限的不良药物反应和药物-药物相互作用以及最小的肝酶升高风险。由于安布森坦具有致畸性的潜在风险，因此只能通过有限的分发计划（即LEAP（莱塔利斯教育与获取计划））获得。正在进行的临床试验将有助于阐明安贝生坦在治疗PAH中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号